Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: RCT
Status:
Not yet recruiting
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
The goal of this study is to target the neurobiology of restricted and repetitive behaviors
in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated
nutritional supplement that has shown promise for reducing symptom severity in recent
small-scale trials. The findings from this research will shed light on the mechanisms of
action underlying the clinical benefits of NAC and the effects of NAC on altering restricted
and repetitive behavior symptom severity in children with autism spectrum disorder. This is a
12-week double-blind, randomized, placebo-controlled trial of NAC.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Stanford University
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)